Retinal angiomatous proliferation occurring after radiotherapy

Eye (Lond). 2013 Mar;27(3):447-9. doi: 10.1038/eye.2012.274. Epub 2013 Jan 4.

Abstract

Purpose: To describe two cases of retinal angiomatous proliferation (RAP)-like lesion following radiation therapy for primary tumor.

Patients and methods: Retrospective evaluation of two patients with previous irradiation treatment for a pleomorphic adenoma of the lacrimal gland and a vocal cord carcinoma, respectively. Visual acuity (VA), fluorescein angiography and optical coherence tomography were performed and demonstrated a RAP-like lesion in both cases. Treatment with intravitreal injections of Ranibizumab was performed with a follow-up of 19 and 10 months, respectively.

Results: Both the patients had a positive response to the treatment with improvement in VA and reduction of intraretinal fluid.

Conclusion: RAP-like lesions can develop following radiation treatment for a primary tumor. In patients presenting with idiopathic RAP, a history of prior radiotherapy should be considered.

Publication types

  • Case Reports

MeSH terms

  • Adenoma, Pleomorphic / pathology
  • Adenoma, Pleomorphic / radiotherapy
  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Eye Neoplasms / pathology
  • Eye Neoplasms / radiotherapy
  • Female
  • Fluorescein Angiography
  • Humans
  • Lacrimal Apparatus Diseases / pathology
  • Lacrimal Apparatus Diseases / radiotherapy
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / radiotherapy
  • Male
  • Radiation Injuries / diagnosis
  • Radiation Injuries / drug therapy
  • Radiation Injuries / etiology*
  • Radiotherapy / adverse effects*
  • Ranibizumab
  • Retina / radiation effects*
  • Retinal Neovascularization / diagnosis
  • Retinal Neovascularization / drug therapy
  • Retinal Neovascularization / etiology*
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Visual Acuity / physiology
  • Vocal Cords / radiation effects

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Ranibizumab